SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant volatility following a post-earnings selloff, driven by a combination of conservative forward guidance and the announcement that co-founder Reed Hastings will step down from the board. While some investors are expressing frustration over the softening outlook and management shifts, the broader community remains divided, with many long-term bulls highlighting the company's strong cash flow and planned share buybacks as an opportunity to buy the dip.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by the company's aggressive and ongoing Bitcoin accumulation strategy alongside concerns regarding share dilution and the sustainability of its preferred securities. The community remains deeply divided, with bulls pointing to the potential for a massive short squeeze as Michael Saylor continues to leverage the firm's balance sheet, while bears warn that the stock is becoming increasingly disconnected from fundamentals and faces significant risks if the crypto market trend reverses.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest news that the company has increased its ownership stake in the Tanbreez rare earths project to 92.5%, a major milestone that has fueled discussions about the company's strategic importance in the Western supply chain. The community is actively debating the stock's potential for a short squeeze, citing high short interest and anticipation that the Greenland-based asset could attract direct government support or major institutional investment.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as market participants closely monitor progress on the Clarity Act and institutional developments, including potential new partnerships and stablecoin activity. The community remains divided between long-term holders betting on utility-driven adoption and skeptics who frequently challenge the asset's price action and historical supply concerns.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing intense trading volume and bullish sentiment driven by the FDA's decision to evaluate reclassifying several restricted wellness peptides, a move that directly benefits the company's existing manufacturing capabilities and telehealth model. The community is heavily focused on the potential for a massive short squeeze, citing high short interest and a series of strategic catalysts that have turned the stock into a focal point for momentum traders.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and renewed optimism as traders monitor key resistance levels near 75k amid speculation surrounding the Clarity Act and institutional accumulation. The community is heavily divided, with bulls pointing to historical supply constraints and institutional support, while bears remain focused on structural resistance and potential downside risks from ongoing geopolitical uncertainty.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing significant volatility and trading volume as investors react to reports of a pending executive order that would advance research into ibogaine for PTSD treatment. The community is actively debating the stock's low-float potential and short-squeeze prospects, while many traders urge caution due to the speculative nature of these biotech-driven rallies and concerns over potential future share dilution.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as investors debate its role as a leveraged proxy for Ethereum, with active community discussion centering on the company's aggressive treasury accumulation strategy and the ongoing tension between its high-level institutional partnerships and persistent share dilution concerns. While some retail shareholders express frustration over the stock's price action decoupling from broader crypto market gains, others remain focused on the potential for a significant upside re-rating as the firm nears its stated Ethereum ownership targets.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant market momentum following a series of bullish analyst initiations, including a notable buy rating and price target, alongside increased investor attention during World Quantum Day. The community is actively discussing the companys strategic partnerships with NVIDIA and its growing role in defense and space sectors, positioning it as a standout quantum play compared to its peers.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as investors monitor its role in high-efficiency power delivery for AI data centers alongside geopolitical pressures affecting the broader semiconductor sector. The community is actively debating the company's valuation, institutional positioning, and the potential for a breakout as traders weigh long-term technological adoption against short-term volatility.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The treatment showed an objective response rate of 44% and a disease control rate of 94%.</li><li>Kura said tumor shrinkage was seen in 75% of the 16 patients on trial.</li><li>The results were presented at the International Kidney Cancer Symposium Europe 2026 in Paris.</li></ul>Shares of Kura Oncology (KURA) jumped more than 13% in pre-market trading on Friday after the clinical-stage biotech firm reported encouraging early data from its ongoing trial for the treatment of advanced kidney cancer.The results, presented at the International Kidney Cancer Symposium Europe 2026 in Paris, focused on patients with clear cell renal cell carcinoma (ccRCC).If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KURA">KURA shares</a> would hit their highest levels since Jan. 7, 2026.<h2 class="st-heading-2">Strong Response Rates, But Small Sample Size</h2>Kura shared initial results from an ongoing FIT-001 trial testing its investigational therapy, Darlifarnib, in combination with Cabozantinib, a type of target enzyme inhibitor, in kidney cancer patients who had already been treated with Cabozantinib.The treatment showed an objective response rate of 44% and a disease control rate of 94%. Tumor shrinkage was seen in 75% of patients, including those who had previously shown limited response to Cabozantinib.Of the 16 patients receiving treatment over an 8- to 56-week period, six are still receiving therapy at the time of the analysis, the company said.<h2 class="st-heading-2">What Investors Should Watch Next</h2>The treatment also demonstrated a manageable safety profile across different dose levels. The study is testing Darlifarnib at daily doses of 3 mg, 5 mg, or 8 mg, taken in cycles of 7 days on and 7 days off, along with daily Cabozantinib at 60 mg or 40 mg. All patients in the study have previously received immunotherapy.The study is now advancing into Phase 1b to further evaluate the optimal dosing and potential benefits of the regimen.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the run-up to start soon.<stembedurl>https://stocktwits.com/mulc/message/650490176</stembedurl>Another user expects “positive news” from the company’s conference call.<stembedurl>https://stocktwits.com/Georgeson/message/650542576</stembedurl>Year-to-date, the stock has shed around 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

The biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer.

Why Did KURA Stock Jump 13% In Pre-Market Today?

Equity

Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital

Lake Street Capital upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday...

Kura Oncology (NASDAQ:KURA) Trading Up 4.8%  - Here's What Happened

Kura Oncology (NASDAQ:KURA) Stock Price Up 4.8% - Should You Buy...

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume  - Time to Buy?

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume - Should You Buy...

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation...

Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00

Mizuho decreased their price target on shares of Kura Oncology from $30.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday...

Implied Volatility Surging for Kura Oncology Stock Options

Investors need to pay close attention to Kura Oncology stock based on the movements in the options market lately.

FY2027 EPS Forecast for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Brookline Capital Acquisition dropped their FY2027 earnings estimates for Kura Oncology in a note issued to investors on Thursday...

Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush

Wedbush reduced their price target on Kura Oncology from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday...

Kura Oncology Q4 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) executives used the company's fourth-quarter and fiscal 2025 earnings call to highlight what CEO Troy Wilson called a defining year, driven by the FDA approval of Komzifti...

Kura Oncology Inc

Investor Update

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Technology – AI, chips, software, cloud

Healthcare – Pharma, biotech, medical devices

Financials – Banks, payments, fintech

Energy – Oil, gas, renewables, uranium

Which sector are you most interested in deploying capital into right now?

Stocktwits

Stocktwits Polls

Investors are optimistic following robust phase 1 data showing a 44% response rate for a new darlifarnib kidney cancer combination treatment.

Sentiment is building around the upcoming April earnings call, with bulls looking for institutional support to break current trading levels.

Current Price	$9.93
Prev Close	$8.94
Open	$9.50
Dividend Yield	0.00%
50-Day Moving Average	$8.48
Beta	1.05
Avg. Volume	1.53M
PE Ratio	-2.81

52-Week High	$12.49
52-Week Low	$5.45
Market Capitalization	$789.67M
EPS (Annual)	-$3.18
Price to Book	4.51
Revenue Per Employee	$259,546.15

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc